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Mesenchymal Stromal Cells from Neonatal Tracheal Aspirates
Demonstrate a Pattern of Lung-Specific Gene Expression
Paul D. Bozyk,1 Antonia P. Popova,2 John Kelley Bentley,2 Adam M. Goldsmith,2
Marisa J. Linn,2 Daniel J. Weiss,3 and Marc B. Hershenson2,4
We have previously isolated mesenchymal stromal cells (MSCs) from the tracheal aspirates of premature neo-
nates with respiratory distress. Although isolation of MSCs correlates with the development of broncho-
pulmonary dysplasia, the physiologic role of these cells remains unclear. To address this, we further
characterized the cells, focusing on the issues of gene expression, origin, and cytokine expression. Microarray
comparison of early passage neonatal lung MSC gene expression to cord blood MSCs and human fetal and
neonatal lung fibroblast lines demonstrated that the neonatal lung MSCs differentially expressed 971 gene
probes compared with cord blood MSCs, including the transcription factors Tbx2, Tbx3, Wnt5a, FoxF1, and Gli2,
each of which has been associated with lung development. Compared with lung fibroblasts, 710 gene probe
transcripts were differentially expressed by the lung MSCs, including IL-6 and IL-8/CXCL8. Differential che-
mokine expression was confirmed by protein analysis. Further, neonatal lung MSCs exhibited a pattern of Hox
gene expression distinct from cord blood MSCs but similar to human fetal lung fibroblasts, consistent with a
lung origin. On the other hand, limiting dilution analysis showed that fetal lung fibroblasts form colonies at a
significantly lower rate than MSCs, and fibroblasts failed to undergo differentiation along adipogenic, osteo-
genic, and chondrogenic lineages. In conclusion, MSCs isolated from neonatal tracheal aspirates demonstrate
a pattern of lung-specific gene expression, are distinct from lung fibroblasts, and secrete pro-inflammatory
cytokines.
Introduction
With improvements in neonatal care, the survival ofvery premature infants has increased. However, en-
hanced survival has been accompanied by an increase in
bronchopulmonary dysplasia (BPD), a fibrotic lung disease
requiring supplemental oxygen for months or years [1]. Sur-
vivors of BPD have abnormal lung function even as young
adults [2], making BPD one of the leading causes of lung
disease in children. The lungs of infants dying fromBPD show
larger and fewer alveoli, as well as poorly formed secondary
crests, indicating an interference with septation [3,4]. Alveolar
septa are thickened with collagen and elongated cells resem-
bling fibroblasts [5]. These cells are positive for both a-smooth
muscle actin and transforming growth factor (TGF)-b, a
stimulus for myofibroblastic differentiation [6]. These results
indicate that BPD may result in part from the abnormal dif-
ferentiation or proliferation of alveolar mesenchymal pro-
genitor cells to myofibroblasts.
Our laboratory has previously isolated plastic-adherent,
fibroblast-like cells from the tracheal aspirates of premature
infants undergoing mechanical ventilation for respiratory
distress [7–9]. These cells possess colony-forming potential,
surface markers, and differentiation potential typically found
in mesenchymal stem cells. Recent work suggests that there
is a hierarchy of multipotent mesenchymal stromal cells
(MSCs) ranging from true self-renewing stem cells with
multilineage differentiation capacity to those with more re-
stricted differentiation potential, until a state of complete
restriction to the fibroblast is reached [10]. Since we have not
thoroughly tested the clonogenicity or in vivo self-renewal of
neonatal lung mesenchymal cells, we now refer to them as
MSCs, which have a more restricted differentiation potential.
Patients from whom MSCs are isolated require more days of
mechanical ventilation and supplemental oxygen, and are
more likely to develop BPD, than patients from whom these
cells are not isolated [7,9]. MSCs differentiate to myofibro-
blasts in vitro [8]. Together, these results suggest that neo-
natal lung MSCs play a significant role in the pathogenesis of
BPD.
At present, the fundamental nature, origin, and physio-
logic role of neonatal lung MSCs are unclear. For example, it
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has not been established whether neonatal lung MSCs orig-
inate from the lung or some other tissue. Adult bone marrow
contains a minority population of cells with characteristics of
MSCs [11]. More recently, it has been suggested that most
organs apparently carry their own population of MSCs in a
perivascular compartment that participate in tissue repair
[12,13]. Consistent with this, MSCs of donor sex identity
have been found in lung allografts years after transplantation
[14]. It is also unclear whether MSCs function as precursor
cells for lung lipofibroblasts or myofibroblasts, or whether
they serve an immunomodulatory role. Finally, the extent to
which lung MSCs differ from lung fibroblasts is not clear. We
hypothesized that MSCs isolated from neonatal lungs ex-
press specific genes indicative of a lung origin. Further,
based on the association of neonatal lung MSCs with adverse
clinical outcomes [7,9], we hypothesized that, compared with
structural lung mesenchymal cells, neonatal lung MSCs
possess a pro-inflammatory phenotype. To address these
hypotheses, we compared the gene expression pattern of
neonatal lung MSCs to cord blood MSCs and diploid fetal
and neonatal lung fibroblasts.
Materials and Methods
Patients
We examined tracheal aspirates from infants admitted to
the University of Michigan C.S. Mott Children’s Hospital
Newborn Intensive Care Unit, as approved by the University
of Michigan Investigational Review Board. Entry criteria
included gestational age at birth less than or equal to 33
weeks, mechanical ventilation for respiratory distress, and
age £ 7 days. Infants with acute sepsis were excluded. In-
fants were suctioned on an as-needed basis. Samples were
collected after informed consent from 1 parent or legal
guardian was obtained.
Cell culture
MSCs from tracheal aspirates of premature infants hos-
pitalized at the University of Michigan were isolated as de-
scribed previously [7], with some modifications. Specimens
were centrifuged (1,200 · g for 5min at 15C) and the cell
pellet resuspended in 2mL Dulbecco’s modified essential
medium supplemented with 10% fetal bovine serum, 100U/
mL penicillin, 100 mg/mL streptomycin, 2mM L-glutamine,
and 2.5 mg/mL amphotericin B. Adherent cells were incu-
bated at 37C and in 5% CO2 and grown until colonies were
established. Neonatal lung MSC colony forming units typi-
cally develop between 7 and 14 days after plating of tracheal
aspirates [7]. Individual colonies were identified and isolated
using cloning disks (PGC Scientifics, Frederick, MD). MSCs
of passage 3 and 4 were studied.
Cord blood MSCs were obtained with Institutional Re-
view Board approval from full-term normal deliveries at the
University of Vermont, as described previously [15]. Briefly,
cord blood monocytes were isolated by Ficoll gradient cen-
trifugation (Fisher Bio-Reagents, Pittsburgh, PA), re-
suspended in 1:1 mixture of cord blood basal medium and
human bone marrow MSC-conditioned medium, plated in
standard culture dishes (Corning, Pittsburgh, PA), and
maintained until colonies were established. Experiments
were performed on passage 3 cells.
The primary fetal/neonatal diploid lung fibroblast lines
MRC-5 (passage 16 cells isolated from 14 week fetus), MRC-9
(passage 7 cells isolated from 15 week fetus), and CCD34-Lu
(passage 6 cells from a patient who died of Rh incompatibility)
were purchased fromATCC (Rockville, MD). These lines were
selected because they are closely related in origin and gesta-
tional age to neonatal lung MSCs. Cells were initially propa-
gated in a T150 flask with ATCC-formulated Eagle’s
minimum essential medium with 10% fetal bovine serum. At
approximately 70% confluence, cells were collected by tryp-
sinization and stored in 10% DMSO at - 80F until use.
After initial cell collection, all cell types were grown under
identical conditions in Dulbecco’s modified essential me-
dium supplemented with MSC grade 10% fetal bovine serum
(Invitrogen, Carlsbad, CA), 100U/mL penicillin, 100 mg/mL
streptomycin, 2mM L-glutamine, and 2.5 mg/mL amphoter-
icin B. For all studies, the medium was changed every 2–3
days.
Differentiation
Passage 3 neonatal lung MSCs and fetal lung fibroblasts
were subjected to differentiation assays along adipogenic,
osteogenic and chrondrogenic lineages as previously de-
scribed, with minor modifications [11]. For adipogenic dif-
ferentiation, passage 3 neonatal lung MSCs were cultured in
standard medium supplemented with dexamethasone
(10 mM), isobutylmethylxanthine (100 mM), indomethacin
(50 mM), and insulin (100 mg/mL). For osteogenic differenti-
ation, cells were cultured in the medium supplemented with
dexamethasone (0.1 mM), b-glycerophosphate (10mM), and
L-ascorbic acid (50 mg/mL). Cells were stained with oil red O
and alizarin red S for identification of fat vacuoles and cal-
cium deposits, respectively. Chondrogenic differentiation
was performed by pelleting 1· 105 cells by centrifugation at
1,200 rpm for 5min. The pellet was placed in media sup-
plemented with 10 ng/mL each of TGF-b1 and bone mor-
phogenic protein-4 for 21 days, fixed in 10% formalin, and
sectioned for Alcian blue staining.
Colony-forming assay
Three colonies arising from the initial plating of tracheal
aspirates from 3 individual subjects were isolated as de-
scribed above, and single cells were obtained by limiting
dilution into 6-well plates. After incubation for 14 days, cells
were washed with phosphate-buffered saline (PBS) and
stained with 0.5% crystal violet (Sigma-Aldrich, St. Louis,
MO) for 15min at room temperature, and visible colonies
counted. Diluted fetal lung fibroblasts were similarly incu-
bated and stained for counting.
Flow cytometry
Passage 3 neonatal lung MSCs were harvested with En-
zyme-Free Hanks-based Cell Dissociation Buffer (Gibco/In-
vitrogen, Carlsbad, CA), pelleted by centrifugation, and
resuspended in PBSwith 50% ethanol for permeabilization and
storage. Before flow cytometry, cells were pelleted and re-
suspended in PBS. Isotype controls and primary antibodies
against cell surface markers typically associated with MSCs
(Stro-1, CD 34, CD45, CD73, CD90, and CD105; BD Pharmin-
gen, San Diego, CA) were added to 100-ml cell suspensions for
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1h at 4C. Cells were washed, and appropriate Alexa fluor
488–tagged secondary antibody (Molecular Probes, Portland,
OR) was added at 1:1,000 dilution for 30min at 4C in the dark.
After washing, cells were immediately analyzed in a
flow cytometer (FACSCalibur; Becton-Dickinson, Franklin
Lakes, NJ).
Gene array
We examined the gene expression profile of 4 individual
neonatal lung MSC isolates, 2 individual cord blood MSC
isolates, and 3 distinct fetal lung fibroblast lines using the Il-
luminaHumanRefSeq-8 v3 expression BeadChip platform (San
Diego, CA). This system covers > 24,000 probes for > 18,000
unique genes from the NCBI RefSeq database. After growth to
approximately 70% confluence on a 100-mm plate, cells were
serum-starved for 24h to minimize differences in cell cycle-
related gene expression, and total RNAwas extracted using the
RNeasy Plus Mini kit (Qiagen, Valencia, CA). Further prepa-
ration and analysis was carried out by the University of Mi-
chigan Sequencing Core, according to the chip manufacturer’s
recommended protocol. Hybridized biotinylated cRNA was
detected with streptavidin-Cy3 and quantitated using the Il-
lumina BeadArray Reader. Microarray results are deposited in
the NCBI GEO database (accession number GSE24583). To
validate the gene array, we performed quantitative 2-step real-
time polymerase chain reaction (qPCR) using specific Syber
green primers. All primers were designed and purchased from
IDT (Coralville, IA).
Analysis of cytokine protein expression
Neonatal lung MSCs and fetal/neonatal lung fibroblast
lines at 70% confluence were serum-deprived for 24 h and
conditioned media were collected for measurement of IL-8,
IL-6, CXCL1/GRO-a, CCL2/MCP-1, hepatocyte growth
factor (HGF), and vascular endothelial growth factor
(VEGF). Protein levels were measured by multiplex immu-
noassay (Bio-Rad, Hercules, CA). For these assays, cells were
seeded at an initial concentration of 1· 105 cells/mL.
Fluorescence microscopy
Neonatal lung MSCs, MRC-5 neonatal lung fibroblasts and
cord blood MSCs were grown on collagen- or fibronectin-
coated glass slides (BD Biosciences, San Jose, CA). Cells were
fixed in 1% paraformaldehyde. Cells were permeabilized in
0.1% Triton X-100 in PBS. Alexa Fluor (AF) dye antibody
conjugates were prepared as previously described [8]. Slides
were probed with AF555-conjugated rabbit anti-human
Wnt5a, AF488-conjugated rabbit anti-human FoxF1, AF633-
conjugated rabbit anti-human Tbx3 (all from Abcam, Cam-
bridge,MA), or similarly labeled rabbit IgG. Cells were imaged
using a Zeiss LSM 150 confocal microscope (Thornwood, NY).
Statistical analysis
For microarray analysis, values for each probe signal on the
BeadChip array were ranked relative to the signals of negative
controls that were thermodynamically equivalent to the reg-
ular probes, but lack specific targets in the transcriptome.
These data were extracted using GenomeStudio Data Analysis
Software (Illumina). Detection P values were computed using
a nonparametric method as 1-R/N, where R is the rank of
the probe signal relative to the negative controls and N is
number of negative controls. A stronger signal has less
probability of being generated from nonspecific sources. Thus,
the detection P value assigns the probability of specific probe
binding to the target transcript. Differences in expression be-
tween lung-derived MSCs, cord blood MSCs, and fetal lung
fibroblasts were analyzed using the Illumina Custom differ-
ential expression algorithm, and multiple tests were corrected
by the Benjamini and Hochberg false discovery rate [16]. The
differential P value reflects the probability of difference be-
tween groups for a given probe. Detection and differential P
values of < 0.05 were determined to be significant. Functional
classifications of target genes was performed using the web-
based program database for annotation, visualization, and
integrated discovery (DAVID) [17,18]. In this analysis, each
identified category is provided a P value against the likeli-
hood of finding the identified category by random chance. An
unpaired 2-way t-test was used to determine the significance
of protein expression data.
Results
Patient data
Lung MSCs from 10 different neonates intubated for re-
spiratory distress were used in this study. Characteristics of
these patients are described in Table 1. The mean gestational
age and birth weight were 29 weeks and 1,267 g, respec-
tively. Six of 10 (60%) babies required supplemental oxygen
at 36 weeks, a clinical definition of BPD [1,19].
Mesenchymal cells from tracheal aspirates
demonstrate cell surface markers and differentiation
potential typical of MSCs
Plastic adherent cells from 3 neonatal tracheal aspirates
were analyzed by flow cytometry (Fig. 1). As shown previ-
ously [7], MSCs were uniformly positive for Stro-1, CD73,
CD90, and CD105, whereas negative for CD45. Cells showed
weak staining for CD34, consistent with previous work
demonstrating a population of CD34-positive in MSCs de-
rived from second trimester fetal lung [20].
Bead array results
The concordance of gene expression between isolates, as
measured by r2 values, was strong within the neonatal lung
MSC (0.9372–0.9563), fetal lung fibroblast (0.9780–0.9854),
and cord blood MSC (0.9521) groups. Intergroup r2 values
were 0.9553 for the tracheal aspirate MSCs and fetal lung
fibroblasts, 0.9016 between the tracheal aspirate MSCs and
cord blood MSCs, and 0.8783 between cord blood MSCs and
fetal lung fibroblasts (Fig. 2). Thus, with regard to the pattern
of gene expression, tracheal aspirate MSCs resembled lung
fibroblasts more than cord blood MSCs.
A detection P value of £ 0.05 identified 13,690 probes from
neonatal lung MSCs, 12,939 probes from fetal lung fibro-
blasts, and 13,050 probes from cord blood MSCs. Comparing
neonatal lung MSCs to cord blood MSCs, signals from 971
gene probes were statistically different (differential P val-
ue< 0.05). As the Illumina Hum-Ref 8 bead array can detect
statistical significance with as little as a 1.3-fold change based
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on average signal strength, we further narrowed our findings
to include fold changes of ‡ 1.5. This resulted in 429 probes
that were upregulated in neonatal MSCs compared with
cord blood MSCs, and 282 that were downregulated. Among
the upregulated genes were those involved in lung devel-
opment, growth factor/cell signaling, inflammation, extra-
cellular matrix, and lipid metabolism (Table 2, and
Supplementary Table S1; Supplementary Data are available
online at www.liebertonline.com/scd).
Comparing neonatal lung MSCs to fetal lung fibroblasts,
there were 710 gene probes of statistically different strength.
Using the 1.5-fold change cutoff, signals from 354 gene
probes were increased and 110 probes were decreased.
Among the upregulated genes were those involved in
growth factor/cell signaling, transcription, extracellular
matrix, inflammation, lipid metabolism, oxidative metabo-
lism, and tight junctions (Table 3, and Supplementary Table
S2). Complete results are provided in the online data sup-
Table 1. Patient Characteristics
Patient Gender Race
Gestational
age (weeks)
Birthweight
(g) Lived BPD
No. of ( + ) samples/
total samples
1 Female Caucacian 28 5/7 1210 Yes Yes 2/2
2 Male Caucacian 28 800 No Yes 1/2
3 Female African-American 29 2/7 1080 Yes No 1/1
4 Female White 27 5/7 845 Yes Yes 2/2
5 Male White 27 1265 Yes Yes 2/2
6 Female White 27 6/7 1615 Yes Yes 3/3
7 Female White 28 5/7 1180 Yes Yes 1/2
8 Male White 31 3/7 1620 Yes No 1/1
9 Female White 29 6/7 1425 Yes No 1/2
10 Female African-American 32 3/7 1630 Yes No 1/1
Mean 29 1267 9/10 6/10
– SD – 1.5 – 306
FIG. 1. Immunophenotypic
analysis of mesenchymal
stromal cells (MSCs) by flow
cytometry. Cells were stained
for CD73, CD90, CD105, and
Stro-1, each of which identi-
fies MSCs. CD34 is mildly
positive, and the endothelial
and hematopoietic cell mark-
ers CD31 and CD45 are neg-
ative. Control reactions were
performed with irrelevant
isotype IgG controls (gray
lines). Typical results from in-
dividual subjects are shown.
The percentage of positive
cells is shown for each marker
(mean – SD, n= 3).
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plement. We also analyzed these upregulated genes using
the DAVID functional annotation tool [17,18]. Categories
representing > 5% of the differentially expressed genes and a
P < 0.01 were selected (Table 4). Unexpectedly, the top 3 gene
ontology (GO) terms each involved lipid biosynthesis and
metabolism.
It has been demonstrated that MSCs and fibroblasts have
characteristic Homeobox (Hox) expression signatures that are
specific for their anatomical origin [21,22]. Comparison of the
Hox gene profiles demonstrated similar expression patterns
between neonatal lung MSCs and fetal lung fibroblasts
(Table 5). The Hox expression profile for cord blood MSC
was distinct, however. Together, these results are consistent
with the notion that MSCs isolated from the tracheal aspi-
rates of premature infants are derived from lung rather than
hematopoietic tissue.
To validate the gene array, we performed qPCR for 7 lung-
specific transcription factors that, according to the gene
array, were significantly overexpressed in lung MSCs com-
pared with cord blood MSCs. Gene expression of FoxF1,
HoxA2, HoxA4, HoxA5, HoxB5, Gli2, andWnt5A was 1–5 logs
higher in neonatal lung MSCs than cord blood MSCs (Fig.
3A). Cells were also examined by fluorescent microscopy.
Neonatal lung MSCs demonstrated increased expression of
FoxF1, Wnt5a, and Tbx3 compared with MRC-5 fetal lung
fibroblasts or cord blood MSCs (Fig. 3B).
Lung MSCs secrete greater levels of cytokines
than fetal lung fibroblasts
As shown in Table 4, the mRNA expression of a number of
cytokines, including IL8 and IL6, was significantly increased
in neonatal lung MSCs compared with fetal lung fibroblasts.
In addition, there were other cytokines, including CXCL1
and CXCL5, expressed in neonatal lung MSCs but not in fetal
lung fibroblasts (data not shown). Differences in CXCL1/
GRO-a, CXCL8/IL-8, and IL-6 were also present at the
protein level (Fig. 4). Compared with fetal/neonatal lung
fibroblasts, MSCs showed no increase in the secretion of
CCL2/MCP-1, HGF, or VEGF.
Differences between MSCs from patients
developing BPD and MSCs from patients
who do not develop chronic lung disease
Of the 9 MSC isolates tested for cytokine/growth factor
protein secretion, 5 were isolated from patients who later
developed BPD and 4 were isolated from patients who did
not. Cells isolated from patients with BPD showed signifi-
cantly decreased secretion of CXCL1/GRO-a and HGF (Fig.
4, P < 0.05, unpaired t test), an epithelial repair factor that has
been shown to suppress bleomycin-induced lung fibrosis
[23–25]. On the other hand, cells from BPD patients showed
greater levels of VEGF (Fig. 3, P< 0.05, unpaired t test), a
growth factor that has been associated with pulmonary fi-
brosis [26]. Together, these results suggest that neonatal lung
MSCs from patients with BPD maintain a stable anti-
inflammatory, pro-fibrotic phenotype.
Lung MSCs, but not fetal lung fibroblasts, undergo
differentiation along mesenchymal lineages and
form colonies at a high rate
Given the similarities in Hox gene expression between
neonatal lung MSCs and fetal/neonatal lung fibroblasts, we
performed additional studies comparing the differentiation
and colony forming potential of these cells. As shown pre-
viously [16], MSC colonies from neonatal tracheal aspirate
underwent adipogenic, osteogenic, and chondrogenic dif-
ferentiation (Fig. 5). Cord blood MSCs were also capable of
differentiation along the 3 mesenchymal lineages [15]. Fetal
lung fibroblasts treated under the same differentiating con-
ditions failed to undergo differentiation. Next, to determine
colony-forming potential, limiting dilution was performed to
generate single cells. On average, 73% of MSCs formed col-
onies when followed over a 14-day period. These results
demonstrate that neonatal lung MSCs are not dependent on
the presence of other cells for survival. However, when cells
from 3 fetal lung fibroblast lines were tested, only 10% of
fetal/neonatal lung fibroblasts formed colonies (P = 0.006).
Together with the cytokine expression data, these results
provide strong evidence that neonatal lung MSCs represent a
distinct subset of lung mesenchymal cells and are qualita-
tively different from lung fibroblasts.
Discussion
Our laboratory has isolated plastic-adherent, fibroblast-
like cells from the tracheal aspirates of premature infants
undergoing mechanical ventilation for respiratory distress.
These cells have the cell surface markers and in vitro dif-
ferentiation potential of MSCs [27]. Patients from whom
MSCs are isolated require significantly more days of me-
chanical ventilation and supplemental oxygen, and develop
FIG. 2. Concordance of gene probe detection P value; P £ 0.05 between tracheal aspirate MSCs, cord blood MSCs, and fetal
lung fibroblasts. Four MSC isolates, 3 fibroblast isolates, and 2 cord blood isolates were studied. Thin black lines signify
1.5-fold change based on average probe signal.
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Table 2. Selected Genes Differentially Expressed in Lung Mesenchymal Stromal Cells
Relative to Cord Blood Mesenchymal Stromal Cells
Symbol
Differential score
P value Fold increase Definition
Development
HOXB5 0.04632 56.85 Homeobox B5
HOXA5 0.03145 36.98 Homeobox A5
FOXF1 0.00008 19.59 Forkhead box F1
LBH 0.00035 10.40 Limb bud and heart development homolog (mouse)
HOXB7 0.00522 9.77 Homeobox B7
WNT5A 0.02439 6.51 Wingless-type MMTV integration site family, member 5A
HOXB6 0.0352 5.84 Homeobox B6
HOXB3 0.00387 3.58 Homeobox B3
TBX3 0.03147 3.54 T-box 3, transcript variant 1
HOXB4 0.00313 3.22 Homeobox B4
HOXA2 0.0344 3.14 Homeobox A2
RUNX1 0 2.53 Runt-related transcription factor 1, transcript variant 1
HOXA4 0.00049 1.95 Homeobox A4
GLI2 0.01815 1.87 GLI-Kruppel family member GLI2
NOTCH1 0.00256 1.85 Notch homolog 1, translocation-associated (Drosophila)
DKK3 0.00183 1.79 Dickkopf homolog 3 (Xenopus laevis), transcript variant 1
SMO 0.00217 1.58 Smoothened homolog (Drosophila)
SPRY2 0.00332 0.67 Sprouty homolog 2 (Drosophila)
NOTCH2 0.00014 0.64 Notch homolog 2 (Drosophila)
MESP1 0.01156 0.58 Mesoderm posterior 1 homolog (mouse)
TWIST1 0.02902 0.53 Twist homolog 1
MEST 0.00323 0.18 Mesoderm specific transcript homolog (mouse), transcript variant 1
Growth factor/cell signaling
IGFBP5 0.00856 5.23 Insulin-like growth factor binding protein 5
PDGFD 0.01156 4.85 Platelet derived growth factor D, transcript variant 1
PDGFD 0.02023 6.47 Platelet derived growth factor D, transcript variant 2
SOCS1 0.00539 2.47 Suppressor of cytokine signaling 1
BMP2K 0.00001 2.25 BMP2 inducible kinase, transcript variant 2
1EGFR 0.00775 2.00 Epidermal growth factor receptor, transcript variant 1
JAK1 0.00496 1.83 Janus kinase 1
RARB 0.00713 0.61 Retinoic acid receptor, beta, transcript variant 1
SMAD7 0.00003 0.49 SMAD family member 7
NGF 0.00143 0.34 Nerve growth factor (beta polypeptide)
STAT1 0.00658 0.33 Signal transducer and activator of transcription 1, transcript variant a
STAT1 0.02745 0.31 Signal transducer and activator of transcription 1, transcript variant b
Extracellular matrix
DCN 0.01358 16.00 Decorin, transcript variant C
LAMA2 0.03535 2.77 Laminin, alpha 2, transcript variant 1
COL6A3 0.00004 2.04 Collagen, type VI, alpha 3 (COL6A3), transcript variant
COL5A1 0.01064 0.62 Collagen, type V, alpha 1
COL1A1 0.01543 0.53 Collagen, type I, alpha 1
LAMC2 0.00551 0.46 Laminin, gamma 2, transcript variant 1
FN1 0 0.22 Fibronectin 1, transcript variant 6
Inflammation
PDE5A 0.02367 11.20 Phosphodiesterase 5A, cGMP-specific, transcript variant 1
PTGER2 0.04076 4.62 Prostaglandin E receptor 2 (subtype EP2)
IRAK3 0.00775 3.80 Interleukin-1 receptor-associated kinase 3
NFKB1 0.00144 1.79 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
PLCG1 0.03371 1.51 Phospholipase C, gamma 1, transcript variant 2
IL1RAP 0.01188 0.58 Interleukin 1 receptor accessory protein, transcript variant 1
TLR4 0.00001 0.28 Toll-like receptor 4
Lipid metabolism
OLR1 0.02776 7.27 Oxidized low density lipoprotein receptor 1
FASN 0.01645 2.23 Fatty acid synthase
ADFP 0.03652 1.66 Adipose differentiation-related protein
Others
CASP1 0.03147 7.71 Caspase 1, apoptosis-related cysteine peptidase
CEBPD 0.00747 6.19 CCAAT/enhancer binding protein, delta
ABCC4 0 4.90 ATP-binding cassette, sub-family C
(continued)
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BPD at a significantly higher rate than patients from whom
these cells were not isolated [9]. In the present study, study
subjects again demonstrated a high prevalence of BPD; 60%
developed BPD, compared with the reported 25% of very
low birth weight premature infants [1]. These data suggest
that MSCs play a role in lung injury, and are not simply the
result of endotracheal intubation. In this report, we further
describe these cells to better understand the role of MSCs in
lung injury, focusing on the issues of gene expression, origin,
and cytokine expression
Until now, we had not examined the origin of tracheal
aspirate neonatal MSCs. Although MSCs were first identified
in bone marrow, MSCs of donor sex identity have been
found in lung allografts years after transplantation, sug-
gesting that MSCs may originate from the lung tissue itself
[14], perhaps from the perivascular compartment [12,13]. It
has also been shown that bone-marrow-derived progenitor
cells may contribute to the population of lung cells found in
the murine lung after either bleomycin [28] or naphthalene-
induced [29] lung injury. To examine this question, we took
advantage of the fact that MSCs and fibroblasts have char-
acteristic Hox expression signatures that are highly specific
for their organ of origin [21,22]. Patterns of MSC Hox gene
expression are not altered by the presence of hematopoietic
cells or by differentiation [22]. These data are consistent with
the notion that MSCs primarily colonize tissues as constitu-
ents of the wall of ingrowing blood vessels [12,13]. Although
cells from neonatal tracheal aspirates and cord blood each
met criteria for MSCs [27], they showed distinct patterns of
Hox gene expression. Several Hox genes implicated in lung
development, including Hoxa2, a4, a5, and b5, were ex-
pressed in neonatal lung MSCs but absent in cord blood
MSCs [27,30–33]. On the other hand, there was a notable
similarity of Hox gene expression between neonatal tracheal
aspirate MSCs and fetal lung fibroblasts, consistent with a
common origin.
Additionally, in contrast to cord blood MSCs, neonatal
lung MSCs expressed several transcription factors important
in pulmonary development. Wnt5a, Tbx2, Tbx3, FoxF1, and
Gli2 were each significantly upregulated compared with
cord blood MSCs. Wnt5a transcripts are detected in mesen-
chymal and epithelial compartments of the developing lung.
Wnt5a knockout mice demonstrate truncation of the trachea
and overexpansion of the distal airways [34,35], highlighting
the importance of Wnt5a in distal lung morphogenesis.
Forkhead Box F1 (FoxF1) is involved in the regulation of
mesenchymal–epithelial interactions critical for lung mor-
phogenesis. FoxF1 heterozygous null mice show defects in
alveolarization and vasculogenesis [36]. FoxF1 heterozygotes
also exhibit decreased expression of members of the Bra-
chyury T-Box gene family Tbx 2–5. Tbx 2–5 encode DNA-
binding transcription factors that are expressed in the
developing lung mesenchyme and regulate branching mor-
phogenesis [37,38]. Together with the Hox gene expression
profile, these data strongly suggest that MSCs from neonatal
tracheal aspirates originate in the lung itself, rather than a
peripheral site such as blood or bone marrow.
Although neonatal lung MSCs and fetal/neonatal lung
fibroblasts demonstrated a similar pattern of Hox gene ex-
pression, comparison of gene expression patterns also re-
vealed important differences, most notably in the areas of
inflammation and lipid metabolism. Increases in cytokine
gene expression were confirmed by analysis of protein levels.
The strong induction of pro-inflammatory cytokines is con-
sistent with the notion that MSCs modulate the inflamma-
tory response [39]. Based on the highly significant induction
of genes involved in lipid biosynthesis and metabolism, as
assessed using the DAVID functional annotation tool [17,18],
as well as the capacity of these cells to undergo adipogenic
differentiation, we speculate that neonatal lung MSCs may
also serve as precursors for alveolar lipofibroblasts. These
cells provide type II cells with neutral lipid for surfactant
synthesis [40] and may play a role in alveolarization [41].
Based the capacity of MSCs to accumulate contractile
proteins under the influence of TGF-b [8], they may also
differentiate into alveolar myofibroblasts. In the mouse,
a-actin- and elastin-expressing myofibroblasts are required
for the formation of pulmonary alveolar secondary septi
[42,43]. However, excessive proliferation or differentiation of
myofibroblasts, as found in infants with BPD [6], can impair
alveolarization. Interestingly, neonatal lung MSCs also
appear to express numerous genes that encode products
associated with either alveolar development (adipose dif-
ferentiation-related protein, adrenomedullin) [44,45] or fi-
brosis (Nox4, coagulation factor X) [46,47]. Thus, the
physiologic role of neonatal lung MSCs may depend on the
differential translation of such genes, as regulated by such
clinical factors as mechanical ventilation, supplemental ox-
ygen, and infection. Consistent with this, we found MSCs
isolated from patients who ultimately developed BPD elab-
orated decreased levels of CXCL1/GRO-a and HGF, and
increased levels of VEGF, compared with isolates from pa-
tients without chronic lung disease. Together, these results
suggest that neonatal lung MSCs from patients with BPD
maintain a stable anti-inflammatory, pro-fibrotic phenotype
that leads to disorganized lung repair.
Finally, we compared the differentiation and colony-
forming potential of neonatal lung MSCs and fetal/neonatal
Table 2. (Continued)
Symbol
Differential score
P value Fold increase Definition
ADM 0.02776 3.42 Adrenomedullin
HDAC1 0.00598 1.50 Histone deacetylase 1
THBS1 0.03937 0.46 Thrombospondin 1
ABCA3 0.02804 0.44 ATP-binding cassette, sub-family A, member 3
TAGLN 0.04238 0.44 Transgelin, transcript variant 1, mRNA
ODC1 0 0.42 Ornithine decarboxylase 1
Diff Pval, differential score P value.
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Table 3. Selected Genes Up-Regulated in Neonatal lung Mesenchymal Stromal Cells
Relative to Fetal/Neonatal Lung Fibroblasts
Symbol
Differential score
P value Fold increase Definition
Growth factor/cell signaling
PTGS2 0.01108 3.37 Homo sapiens prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and cyclooxygenase)
IRS2 0 3.24 Insulin receptor substrate 2
RHOB 0 2.98 ras homolog gene family, member B
POSTN 0.00002 2.64 Periostin, osteoblast specific factor
PDGFRB 0.02029 2.02 Platelet-derived growth factor receptor, beta polypeptide
FZD4 0.03599 1.99 Frizzled homolog 4 (Drosophila)
BMP2K 0.00011 1.96 BMP2 inducible kinase, transcript variant 2
ADCY3 0.02648 1.93 Adenylate cyclase 3
BMP2K 0.00309 1.74 BMP2 inducible kinase, transcript variant 1
FYN 0.00197 1.83 FYN oncogene related to SRC, FGR, YES, transcript variant 3
FYN 0.0001 1.80 FYN oncogene related to SRC, FGR, YES, transcript variant 2
FYN 0.01167 1.79 FYN oncogene related to SRC, FGR, YES, transcript variant 1
PIK3R1 0.0031 1.67 Phosphoinositide-3-kinase, regulatory subunit 1 (a), transcript variant 1
JAK1 0.03598 1.63 Janus kinase 1
TANK 0.04767 1.58 TRAF family member-associated NFKB activator, transcript variant 1
PTEN 0.00707 1.52 Phosphatase and tensin homolog
ROCK1 0.00059 1.57 Rho-associated, coiled-coil containing protein kinase 1
BMP4 0.01126 0.56 Bone morphogenetic protein 4, transcript variant 1
SFRP1 0.00013 0.19 Secreted frizzled-related protein 1
Transcription
NKX3-1 0.04772 2.96 NK3 homeobox 1
TCF4 0.00002 2.19 Transcription factor 4, transcript variant 2
ATF4 0.0005 2.12 Activating transcription factor 4, transcript variant 2
GLI2 0.00344 2.09 GLI-Kruppel family member GLI2
KLF6 0.0292 1.91 Kruppel-like factor 6, transcript variant 1
KLF6 0.00381 1.88 Kruppel-like factor 6, transcript variant 2
CREBBP 0.04601 1.64 CREB binding protein, transcript variant 1
CEBPG 0.01062 1.60 CCAAT/enhancer binding protein (C/EBP), gamma
GLI3 0.02884 1.63 GLI-Kruppel family member GLI3
ATF4 0.01673 1.57 Activating transcription factor 4, transcript variant 1
HDAC6 0.01317 1.53 Histone deacetylase 6
SP3 0.00093 1.52 Sp3 transcription factor, transcript variant 2
Extracellular matrix
COL8A1 0.0333 2.82 Collagen, type VIII, alpha 1, transcript variant 2
COL16A1 0 2.32 Collagen, type XVI, alpha 1
COL5A2 0.00101 2.12 Collagen, type V, alpha 2
COL5A1 0.01915 2.05 Collagen, type V, alpha 1
COL3A1 0.00002 1.97 Collagen, type III, alpha 1
COL8A1 0.04255 1.68 Collagen, type VIII, alpha 1, transcript variant 1
LAMB1 0.00984 1.56 Laminin, beta 1
VTN 0.00739 0.56 Vitronectin
Inflammation
IL8 0 24.50 Interleukin 8
IL6 0.00772 4.26 Interleukin 6
CXCL2 0.01386 3.75 Chemokine (C-X-C motif) ligand 2
NFKB1 0.0001 1.72 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
F10 0.03067 1.67 Coagulation factor X
CCL20 0.04759 1.54 Chemokine (C-C motif) ligand 20
ADAM17 0.01387 1.62 ADAM metallopeptidase domain 17
MMP2 0.02185 1.53 Matrix metallopeptidase 2
IL17D 0.00856 0.63 Interleukin 17D
TIMP1 0.02736 0.57 TIMP metallopeptidase inhibitor 1
PLAU 0.01751 0.40 Plasminogen activator, urokinase
PTGER2 0 0.33 Prostaglandin E receptor 2 (subtype EP2)
Lipid metabolism
FABP3 0.0445 5.95 Fatty acid binding protein 3
FADS1 0.00047 4.16 Fatty acid desaturase 1
FADS2 0.00736 3.60 Fatty acid desaturase 2 (FADS2)
LDLR 0.00001 2.61 Low density lipoprotein receptor
FASN 0.01282 2.48 Fatty acid synthase
(continued)
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lung fibroblasts. We confirmed that the plastic-adherent,
colony-forming cells isolated from the tracheal aspirates of
premature infants with respiratory distress meet the criteria
for MSCs on the basis of cell surface markers, ability to dif-
ferentiate along adipogenic, osteogenic, and chondrogenic
lineages, and ability to generate colonies [27]. These data also
support the notion that MSCs do not require support from
other cells to expand in an in vitro environment. In contrast,
fetal lung fibroblasts generated colonies to a much lower
extent than MSCs, and failed to undergo significant mor-
phological changes in differentiation media.
We acknowledge some drawbacks of our study. First,
several factors may affect gene expression and cytokine
production from the cells, making comparisons difficult. For
example, we studied commercially available, higher passage
fetal and neonatal lung fibroblasts, rather than primary
neonatal lung fibroblasts. Two of these lines were obtained
from extremely early lungs, raising the possibility of matu-
rational differences in gene expression. Differences in meth-
ods of cell isolation and health status may also have affected
our results. Due to ethical concerns, the neonatal primary
cells are not readily available. However, one could argue that
use of higher passage fetal lung fibroblast cell lines might
select for more rapidly dividing primitive cells, or favor the
acquisition of mutations enhancing colony forming potential.
Nevertheless, fetal lung fibroblasts showed minimal ability
to form clones after limiting dilution, or to differentiate
among mesenchymal lineages. Second, whereas Hox gene
and transcription factor profiles strongly suggest that neo-
natal tracheal aspirate MSCs from tracheal aspirates are in-
deed lung-derived, we acknowledge the possibility that they
could originate in the bone-marrow and undergo change to a
lung phenotype upon exposure to the pulmonary milieu.
Answering this question conclusively would require more
sophisticated methods such as lineage tagging, which cannot
be accomplished in newborn infants. However, as we noted
above, it has been shown that patterns of MSC Hox gene
expression are not altered by the presence of hematopoietic
Table 3. (Continued)
Symbol
Differential score
P value Fold increase Definition
PPARG 0 0.26 Peroxisome proliferator-activated receptor gamma, transcript variant 2
Oxidation
GPX7 0.00003 3.47 Glutathione peroxidase 7
NOX4 0.04887 3.09 NADPH oxidase 4
SOD2 0.03437 2.78 Superoxide dismutase 2, mitochondrial, nuclear gene encoding
mitochondrial protein, transcript variant 2
Tight junctions
CGNL1 0.02648 3.06 Cingulin-like 1
PANX2 0.00001 2.32 Pannexin 2
TJP1 0.00096 1.65 Tight junction protein 1 (zona occludens 1), transcript variant 2
TJP1 0.02132 1.57 Tight junction protein 1 (zona occludens 1), transcript variant 1
Diff Pval, differential score P value.
Table 4. Functional Classifications of Target Genes Was Performed Using the Web-Based Database
for Annotation, Visualization, and Integrated Discovery Program
Term Count Percent P value
Lipid biosynthetic process 24 7.3 2.90E-10
Cellular lipid metabolic process 36 11 3.20E-10
Lipid metabolic process 38 11.6 5.40E-09
Steroid metabolic process 17 5.2 1.00E-07
Alcohol metabolic process 19 5.8 8.40E-06
Biosynthetic process 48 14.7 3.00E-05
Response to stress 35 10.7 2.80E-04
Apoptosis 27 8.3 7.00E-04
Programmed cell death 27 8.3 7.90E-04
Cellular metabolic process 164 50.2 1.10E-03
Protein modification process 48 14.7 1.30E-03
Death 27 8.3 1.70E-03
Cell death 27 8.3 1.70E-03
Biopolymer modification 48 14.7 2.90E-03
Metabolic process 176 53.8 3.40E-03
Primary metabolic process 161 49.2 4.20E-03
Negative regulation of biological process 33 10.1 4.60E-03
Organ development 35 10.7 4.90E-03
Post-translational protein modification 39 11.9 7.90E-03
Negative regulation of cellular process 31 9.5 8.20E-03
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Table 5. Expression of Homeobox Genes
Neonatal lung mesenchymal stromal cells Fetal lung fibroblasts Cord blood mesenchymal stromal cells
Symbol
Average
probe signal
Detection
P value
Average
probe signal
Detection
P value
Average
probe signal
Detection
P value
HOXA2 149.4 0 132.7 0 47.6 0.57078
HOXA4 88.1 0.00452 79.9 0.01205 45.2 0.85542
HOXA5 1575.5 0 2462.3 0 42.6 0.95633
HOXA6 65.5 0.02108 97.1 0.00301 59.6 0.06928
HOXA9 41 0.59639 58.5 0.03614 52.7 0.18223
HOXB1 94.7 0.00301 93.7 0.00301 96.7 0.00602
HOXB2 610.3 0 397.9 0 288.9 0
HOXB3 163.6 0 98.6 0.00301 45.7 0.76506
HOXB4 162 0 132.7 0 50.3 0.33434
HOXB5 3331.2 0 3890.6 0 58.6 0.07681
HOXB6 65.9 0.02108 65.6 0.01657 72.8 0.01657
HOXB6 397.2 0 355.2 0 68 0.02259
HOXB7 439.6 0 516 0 45 0.80723
HOXB8 48.2 0.14006 258.1 0 44.6 0.9006
HOXC11 72.1 0.01657 68.5 0.01657 76.2 0.01355
HOXC4 41.6 0.51355 59.2 0.03614 47.1 0.68524
HOXC6 47.1 0.16566 172.6 0 52.5 0.2259
HOXC8 45.3 0.24849 95 0.00301 51.5 0.28313
HOXD12 152 0 142.9 0 133.4 0
HOXD13 109.4 0.00301 104.9 0.00301 97.3 0.00602
HOXD3 73.6 0.01657 69.4 0.01657 83.3 0.01054
Bold font indicates that the given probe achieved statistical significance for detection. Only Hox genes expressed in at least 1 cell line were
shown.
FIG. 3. Neonatal lung MSCs express higher
levels of lung-specific transcription factors
than cord blood MSCs. (A) mRNA expres-
sion of FoxF1, HoxA2, HoxA4, HoxA5, HoxB5,
Gli2, and Wnt5A was assessed by qPCR.
Data were normalized to GAPDH. (B–H).
Immunocytochemistry of neonatal lung
MSCs, fetal lung fibroblasts, and cord blood
MSCs. Cells were probed for Wnt5a (red),
FoxF1 (green), and Tbx3 (blue). Colocaliza-
tion is white. (B) Neonatal lung MSCs. (C)
MRC-5 fetal lung fibroblasts. (D) Cord blood
MSCs. (E–G) Individual channels for Wnt5a,
FoxF1, and Tbx3. (H) MRC-5 fetal lung fi-
broblasts stained with labeled control IgGs.
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cells or by differentiation [22]. Third, our study does not
address the potential role of lung- or bone marrow-derived
MSCs in the pathogenesis or treatment of neonatal lung in-
jury. In contrast to our study, in which MSCs are associated
with an adverse pulmonary outcome, administration of
bone-marrow-derived MSCs, or their conditioned media, has
been shown to ameliorate hyperoxia-induced murine neo-
natal lung injury [48,49]. The reason for these discrepant
outcomes is unclear, but the most obvious explanation likely
relates to the different microenvironments to which lung-
and bone marrow-derived MSCs are exposed. Finally, as
touched on above, the study of cells derived from newborn
human infants makes it impractical to perform the experi-
mental interventions necessary to definitively prove MSC
origin or function. Nevertheless, we believe that our careful
characterization of these cells, combined with outcomes data
and the development of appropriate animal models, will
ultimately link lung MSCs to lung injury and repair.
In conclusion, we have isolated and characterized MSCs
from tracheal aspirates of premature neonates with respi-
ratory distress. This present study strengthens the concept
that these cells are indeed progenitor cells, as evidenced by
their ability to form clones from single cells and differenti-
ate along mesenchymal lineages, in contrast to fetal lung
FIG. 4. Cytokine secretion
by neonatal lung MSCs and
fetal lung fibroblasts. Passage
3 neonatal lung MSCs se-
creted greater amounts of
CXCL1/GRO-a, CXCL-8/IL-
8, and IL-6 (n = 9) compared
with the 3 isolates of fetal/
neonatal lung fibroblasts tes-
ted (*P < 0.05, unpaired t-test).
There was no statistical dif-
ference in the secretion of
CCL2/MCP-1, hepatocyte
growth factor, or vascular
endothelial growth factor.
FIG. 5. Differentiation capa-
bility of neonatal lung MSCs
and fetal lung fibroblasts. Un-
der adipogenic conditions, lipid
droplets are revealed with
staining by with oil red O (A–
C). Osteogenic growth condi-
tions create calcium deposits
seen after staining with alizarin
red (D–F). Chondrogenic dif-
ferentiation promotes produc-
tion of glycosaminoglycans,
which are detected by staining
with Alcian blue (G–I). Neona-
tal lung MSCs, but not fetal
lung fibroblasts, differentiate
along these lineages. We ana-
lyzed 3 MSC isolates, 3 fibro-
blast isolates, and 2 cord blood
MSC isolates, and all yielded
the same results.
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fibroblasts. Further, based on their Hox gene profile and
expression of lung transcription factors, our data support the
notion that these cells are lung-derived. Finally, compared
with fetal/neonatal lung fibroblasts, MSCs demonstrate in-
creased expression of pro-inflammatory cytokines. Further
studies will be required to understand the precise physio-
logical role of these cells in lung development and repair.
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